One of 2021's star biotech play­ers flags an­oth­er big set­back for the pipeline

Two months af­ter scut­tling their lead drug, Centes­sa’s ex­ec­u­tive team is back with the lat­est in a se­ries of set­backs that have tanked its stock and blown holes in its strate­gic line­up of biotech subs.

The com­pa­ny re­port­ed in its Q2 post to­day that it has de­cid­ed to scrap ZF874 af­ter a pa­tient demon­strat­ed el­e­vat­ed liv­er en­zymes — a clas­sic red safe­ty flag — in a Phase I study for al­pha-1-an­tit­rypsin (A1AT).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER